Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | SCN4A | P35499 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31109007 | 0.94 | KIF11 (0.65) | KIF11KMT2AMEN1MAOBPARP10 | |
| SCHEMBL4246486 | 0.88 | KMT2A (0.55) | KIF11KMT2AMEN1MAOBPARP10 | |
| SCHEMBL6284986 | 0.87 | KMT2A (0.64) | KIF11KMT2AMEN1PARP10ALDH1A1 | |
| SCHEMBL21551494 | 0.82 | MAOB (0.43) | KIF11KMT2AMAOBPARP10ALDH1A1 | |
| SCHEMBL28783426 | 0.81 | KMT2A (0.53) | KIF11KMT2AMEN1MAOBPARP10 | |
| Guanidine SCHEMBL27421363 | 0.80 | KMT2A (0.45) | KIF11KMT2AMEN1MAOBPARP10 | |
| SCHEMBL57245 | 0.80 | KMT2A (0.50) | KMT2AMEN1ALDH1A1ATMCES2 | |
| SCHEMBL3741169 | 0.79 | KMT2A (0.54) | KIF11KMT2AMEN1MAOBPARP10 | |
| Guanidine SCHEMBL6814628 | 0.79 | KMT2A (0.44) | KMT2AMAOBPARP10ALDH1A1KCNN4 | |
| SCHEMBL14389790 | 0.78 | KMT2A (0.46) | KMT2AALDH1A1ATMCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 599 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299568-A1 | BONE-SPECIFIC DELIVERY OF POLYPEPTIDES | WILLIAM MARSH RICE UNIVERSITY (US) | 2024-09-12 | — | — | US | claimed |
| CN-117529338-A | Bone-specific delivery of polypeptides | 威廉马歇莱思大学 | 2024-02-06 | — | — | CN | claimed |
| EP-4281116-A1 | BONE-SPECIFIC DELIVERY OF POLYPEPTIDES | William Marsh Rice University (US) | 2023-11-29 | — | — | EP | claimed |
| CN-114957112-B | (2-chloroquinoline-3-yl) methyl (N-p-fluorophenyl) carbamate and preparation method and application thereof | 渤海大学 | 2023-01-17 | — | — | CN | claimed |
| CN-114957112-A | (2-chloroquinoline-3-yl) methyl (N-p-fluorophenyl) carbamate and preparation method and application thereof | 渤海大学 | 2022-08-30 | — | — | CN | claimed |
| WO-2022159492-A1 | BONE-SPECIFIC DELIVERY OF POLYPEPTIDES | WILLIAM MARSH RICE UNIVERSITY (US) | 2022-07-28 | — | — | WO | claimed |
| CN-113214339-A | Panaxadiol derivatives, preparation method and medical application thereof | 延边大学 | 2021-08-06 | — | — | CN | claimed |
| US-11076600-B2 | Mixtures of cis-jasmone and bacillus amyloliquefaciens | BASF SE (DE) | 2021-08-03 | — | — | US | claimed |
| CN-106831792-B | A kind of preparation method of PARP inhibitor Rucaparib intermediate | 李绵利 | 2019-02-12 | — | — | CN | claimed |
| US-20180360041-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | BASF SE (DE) | 2018-12-20 | — | — | US | claimed |
| CN-101257798-A | Fungicidal mixtures comprising substituted 1-methylpyrazol-4-ylcarboxanilides | BASF SE (DE) | 2008-09-03 | — | — | CN | claimed |
| CN-101247723-A | Fungicide mixtures based on 3-monosubstituted pyrazole carboxylic acid biphenyl amides | BASF SE (DE) | 2008-08-20 | — | — | CN | claimed |
| CN-101217873-A | Fungicidal mixtures made from 1-methylpyrazol-4-ylcarboxanilides | BASF AG (DE) | 2008-07-09 | — | — | CN | claimed |
| CN-101212900-A | Fungicide mixtures based on 2,4-disubstituted pyrazole carboxylic acid biphenylamides | BASF AG (DE) | 2008-07-02 | — | — | CN | claimed |
| CN-101212902-A | Fungicidal mixtures based on 3, 5-disubstituted pyrazole carboxylic acid biphenylamides | BASF AG (DE) | 2008-07-02 | — | — | CN | claimed |
| CN-101212901-A | Fungicidal mixtures based on 2,5-disubstituted pyrazol carboxylic acid biphenylamides | BASF AG (DE) | 2008-07-02 | — | — | CN | claimed |
| CN-101166733-A | Pyrazole derivatives as phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2008-04-23 | — | — | CN | claimed |
| EP-1904446-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | claimed |
| WO-2007007282-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | claimed |
| CN-1826324-A | Indazole, benzisoxazole and benzisothiazole kinase inhibitors | ABBOTT LAB (US) | 2006-08-30 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11076600-B2 | Mixtures of cis-jasmone and bacillus amyloliquefaciens | BAX, FASN, BAK1 | KIF11 4675/4885KMT2A 4623/4885MEN1 481/4885 |
| US-20180360041-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | SQOR, COX5B, UQCRB | KIF11 3125/4885KMT2A 3197/4885MEN1 2720/4885 |
| US-20240299568-A1 | BONE-SPECIFIC DELIVERY OF POLYPEPTIDES | SOST, BST2, ACP3 | KIF11 1287/4885KMT2A 3635/4885MEN1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.